NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- The global lancet market, generated $830.3 million revenue in 2019, is projected to experience a 9.5% CAGR between 2020 and 2030, according to P&S Intelligence.
A lancet is a pen-like device, which contains a needle connected to a spring, meant to draw sufficient blood, in a minimally invasive manner.
Around 17.9 million die as a result of cardiovascular diseases (CVDs) and 9.6 million as a result of cancer, every year, says the World Health Organization (WHO). Moreover, over 250 million suffer from chronic obstructive pulmonary disease (COPD), 235 million have asthma, and 422 million are living with diabetes. A lot of these diseases can be detected early via blood tests, which is the primary reason for the increasing demand for lancets.
Get a sample copy of this report at: https://www.psmarketresearch.com/market-analysis/lancet-market/report-sample
Safety Lancets to Continue Generating Higher Revenue till 2030
Till 2030, the safety bifurcation is predicted to continue generating higher revenue in the lancet market, as the preference for these devices is high, on account of their better safety profile. Owing to their single-use design, they reduce the chances of infection spread; similarly, with the needle automatically springing back after use, the risk of unintentional pricks and injuries is minimized. Additionally, they eliminate the requirement for lancing devices, which makes them easier to use, for testing the capillary blood.
The glucose testing category held the largest share in the market during the historical period (2014–2019), on account of the rising number of people suffering from diabetes. For ascertaining the severity of the pancreatic disorder and managing it, it is important to monitor the level of glucose in the blood, which is why the requirement for lancets is surging around the world.
Browse report overview with 258 tables and 51 figures spread through 240 pages and detailed TOC on "Lancet Market: Industry Analysis and Growth Forecast to 2030" at: https://www.psmarketresearch.com/market-analysis/lancet-market
In 2019, the lancet market was dominated by the 28 division, as this gauge size means a small-diameter needle, which, in turn, results in minimal pain and discomfort for the patient. Additionally, lancets with a gauge size of 28 are able to draw sufficient blood for the test, which is why they are being rapidly adopted for diabetes diagnosis and management.
The hospitals and clinics classification is expected to display the fastest market growth, at a CAGR of 10.0%, during the forecast period. This is ascribed to the increasing number of such healthcare establishments around the world, where the pool of patients suffering from chronic diseases is also constantly expanding, thereby resulting in a high procurement rate of lancets.
North America was the largest lancet market during the historical period, as a result of the technological advancements in medical devices, growing population of the elderly, and rising incidence of chronic diseases. According to the U.S. Department of Health and Human Services, people in the age group of 65 and above numbered 49.2 million in 2016, and this population will further surge to 98 million by 2060. In the coming years, Asia-Pacific (APAC) would witness the most rapid market advance, owing to the surging geriatric population, rapid economic growth, improving healthcare infrastructure, rising prevalence of chronic diseases, and increasing number of initiatives by public and private organizations to create awareness on diabetes.
Make enquiry before purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=lancet-market
Players Taking Concrete Measures for Increased Profits
The lancet market is witnessing a high rate of strategic measures, as the players are stepping up efforts to gain a larger revenue share in the industry.
For instance, in October 2019, LifeScan Inc. introduced lancets under the OneTouch Delica Plus brand that smoothly glide into the skin, due to their silicone coating.
Furthermore, in July 2019, Osaka-based NIPRO Corporation signed an agreement with Owen Mumford Ltd. to sell the latter organization’s UniSafe, a series of springless devices, in the healthcare market of Japan.
The most prominent global lancet market players include F. Hoffmann-La Roche Ltd., B. Braun Melsungen AG, Abbott Laboratories, Medline Industries Inc., Becton, Dickinson and Company, Terumo Corporation, LifeScan IP Holdings LLC, Owen Mumford Limited, AgaMatrix Inc., Ascensia Diabetes Care Holdings AG, Trividia Health Inc., HTL-STREFA S.A., ACON Laboratories Inc., Ypsomed Holding AG, and SARSTEDT AG & Co. KG.
Other Latest Published Reports by P&S Intelligence
Aspiration and Biopsy Needles Market
Needle-Free Diabetes Management Market
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com